Marcel Nijland
dr.
I work as a hematologist and my main focus is on patients with aggressive B-cell lymphomas and CNS lymphomas. My research is centered on the application of novel diagnostic and therapeutic strategies into clinical trials. These include imaging-studies like 18F-FDG-PET, Zr-Brentuximab-PET and Zr-atezolizumab-PET. In addition, I aim to implement novel strategies to measure minimal residual disease, and prognostic gene expression profiles in DLBCL. Linked to this I also focus on mutational analysis to study clonal evolution and prognostic / predictive values of mutations. These studies are carried out in a close collaboration with HOVON and other departments in the UMCG.
Disturbed antigen presentation in classical Hodgkin Lymphoma; implications for immune checkpoint inhibitor therapy
Immune checkpoint inhibitors are being tested in clinical trials and show great promise in the treatment of classical Hodgkin lymphoma (cHL). The proposed mechanism of action of these inhibitors consists of reactivating T lymphocytes that have become unresponsive as a consequence of inhibitory mechanisms exerted by the tumor cells. These reactivated T cells are expected to kill tumor cells after recognizing tumor cell derived antigens that are presented by Human Leukocyte Antigens (HLA) at the tumor cell surface. Consequently, lack of tumor cell surface expression of HLA may...
M. Nijland, Lydia Visser, Rianne Veenstra, K. Kushekhar, G. van Imhoff, Anke Berg, van den, A. Diepstra
Disturbed antigen presentation in classical Hodgkin Lymphoma; implications for immune checkpoint inhibitor therapy
Immune checkpoint inhibitors are being tested in clinical trials and show great promise in the treatment of classical Hodgkin lymphoma (cHL). The proposed mechanism of action of these inhibitors consists of reactivating T lymphocytes that have become unresponsive as a consequence of inhibitory mechanisms exerted by the tumor cells. These reactivated T cells are expected to kill tumor cells after recognizing tumor cell derived antigens that are presented by Human Leukocyte Antigens (HLA) at the tumor cell surface. Consequently, lack of tumor cell surface expression of HLA may...
M. Nijland, Lydia Visser, Rianne Veenstra, K. Kushekhar, G. van Imhoff, Anke Berg, van den, A. Diepstra
Treatment of initial central nervous system involvement in systemic aggressive lymphoma with high dose methotrexate and R-Cho
Treatment of initial central nervous system involvement in systemic aggressive lymphoma with high dose methotrexate and R-Cho
Efficacy of cisplatin-based immunochemotherapy plus alloSCT in high-risk chronic lymphocytic leukemia: final results of a prospective multicenter phase 2 HOVON study
Published in: Bone marrow transplantation
Access to document
10.1038/bmt.2016.9
Allogeneic stem cell transplantation (alloSCT) remains the only curative option for CLL patients. Whereas active disease at the time of alloSCT predicts poor outcome, no standard remission-induction regimen exists. We prospectively assessed outcome after cisplatin-containing immune-chemotherapy (R-DHAP) followed by alloSCT in 46 patients (median age 58 years) fulfilling modified European Society for Blood and Marrow Transplantation (EBMT) CLL Transplant Consensus criteria being refractory to or relapsed (R/R) <1 year after fludarabine or <2 years after fludarabine-based immunochemotherapy or R/R with del(17p). Twenty-nine patients received ⩾3 cycles of R-DHAP...
M. van Gelder, M. H. van Oers, W. G. Alemayehu, M. C. J. Abrahamse-Testroote, J. J. Cornelissen, M. E. Chamuleau, P. Zachee, M. Hoogendoorn, M. Nijland, E. J. Petersen, A. Beeker, G-J Timmers, L. Verdonck, M. Westerman, O. de Weerdt, A. P. Kater